Get the Stockscreener App
101.51
0.91%
-0.924
Boston Scientific Corp stock is traded at $101.51, with a volume of 2.44M.
It is down -0.91% in the last 24 hours and up +3.38% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$102.43
Open:
$102.31
24h Volume:
2.44M
Relative Volume:
0.29
Market Cap:
$150.40B
Revenue:
$19.35B
Net Income/Loss:
$2.78B
P/E Ratio:
54.29
EPS:
1.8696
Net Cash Flow:
$3.49B
1W Performance:
+1.60%
1M Performance:
+3.38%
6M Performance:
-0.67%
1Y Performance:
+19.75%
1-Day Range:
$101.20
$102.86
1-Week Range:
$100.55
$105.49
52-Week Range:
$80.64
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
101.50 | 151.78B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
ABT
Abbott Laboratories
|
127.25 | 221.35B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
SYK
Stryker Corp
|
378.69 | 146.70B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
93.95 | 120.73B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.12 | 47.45B | 5.69B | 1.41B | 577.90M | 6.9828 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Can Boston Scientific Corporation stock sustain revenue momentumLayoff News & Verified Momentum Stock Alerts - newser.com
Risk vs reward if holding onto Boston Scientific Corporation2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Will Boston Scientific Corporation stock gain from strong economyAnalyst Downgrade & Low Risk Profit Maximizing Plans - newser.com
How Boston Scientific Corporation stock moves in volatile trading sessions2025 Stock Rankings & Expert Approved Momentum Ideas - newser.com
Is Boston Scientific Corporation stock ready for a breakoutShort Setup & Daily Technical Forecast Reports - newser.com
What market sentiment indicators show for Boston Scientific Corporation stockDip Buying & Long-Term Safe Return Strategies - newser.com
Boston Scientific’s Innovative Approach to Gastric Outlet Obstruction: Study Update - TipRanks
Boston Scientific’s SIMPLAAFY Trial: A New Frontier in Atrial Fibrillation Treatment - TipRanks
Boston Scientific’s Orbera365™ Study: A New Frontier in Weight Loss Management - TipRanks
Boston Scientific’s RHAPSODY Study: A Step Forward in Cardiac Care Innovation - TipRanks
Boston Scientific’s Hot AXIOS™ Stent Study: A Potential Game-Changer in Bile Duct Drainage - TipRanks
Boston Scientific’s Innovative Approach to Atrial Fibrillation: A Study Update - TipRanks
Boston Scientific’s Vercise™ DBS Study: A Real-World Evaluation of Dystonia Treatment - TipRanks
Chart based analysis of Boston Scientific Corporation trends2025 Dividend Review & Stepwise Trade Execution Plans - newser.com
Boston Scientific shares positive Agent drug-coated balloon findings - MassDevice
Does Boston Scientific (BSX) Have the Potential to Rally 25.61% as Wall Street Analysts Expect? - Yahoo Finance
Is Boston Scientific Corporation stock a buy in volatile marketsWeekly Trend Recap & Accurate Technical Buy Alerts - newser.com
Boston Scientific Hits Day High with 3.95% Surge, Outperforming S&P 500 - Markets Mojo
Comparing Boston Scientific Corporation in custom built stock radarsMarket Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Evaluating Boston Scientific Corporation with trendline analysisJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Boston Scientific Corporation (BSX) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Truist Financial Remains a Buy on Boston Scientific (BSX) - The Globe and Mail
Fund Update: PARNASSUS INVESTMENTS, LLC added 6,868,459 shares of BOSTON SCIENTIFIC (BSX) to their portfolio - Quiver Quantitative
Boston Scientific Corporation (NYSE:BSX) Q3 2025 Earnings Call Transcript - Insider Monkey
Should Boston Scientific’s (BSX) Upbeat Q3 Results and Raised Guidance Prompt Investor Action? - Yahoo Finance
Boston Scientific Corporation (BSX) Announces Board Member John E. Sununu's Decision Not to Seek Re-election - GuruFocus
Boston Sci Farapulse, Watchman boost Q3 performance - BioWorld MedTech
Boston Scientific director John E. Sununu to step down after 2026 annual meeting - Investing.com
Boston Scientific Announces Board Member Departure - TradingView
Boston Scientific Delivers Robust Q3 Despite Tariff Headwinds: Analyst - Benzinga
BSX Q3 Deep Dive: WATCHMAN and Electrophysiology Drive Outperformance, Guidance Raised - The Globe and Mail
BSX: Morgan Stanley Raises Price Target on Boston Scientific | B - GuruFocus
BSX: Today's Analyst Ratings Maintain Boston Scientific's Buy Ra - GuruFocus
Here's Why Boston Scientific (BSX) is a Strong Growth Stock - Yahoo Finance
Wells Fargo Raises Price Target for Boston Scientific (BSX) to $125 | BSX Stock News - GuruFocus
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Boston Scientific stock price target raised by UBS to $140 on strong growth - Investing.com
Boston Scientific stock price target raised to $130 from $128 at Leerink - Investing.com
GCC $1.25+ Bn Catheter Market Growth Trends and Forecast to - GlobeNewswire
GCC $1.25+ Bn Catheter Market Growth Trends and Forecast to 2033 Featuring Abbott, Edwards Lifesciences, BD and Co, Boston Scientific, Medtronic, Johnson & Johnson, Stryker, Teleflex - Yahoo Finance
Boston Scientific Corp (BSX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Boston Scientific (BSX): Earnings Jump 37%, Profit Margins Beat Bull Case Expectations - Yahoo
Boston Scientific: Q3 Earnings Snapshot - New Haven Register
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):